JP Morgan Initiates Coverage On Kailera Therapeutics with Overweight Rating, Announces Price Target of $30

Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc.

KLRA

0.00

JP Morgan analyst Hardik Parikh initiates coverage on Kailera Therapeutics (NASDAQ: KLRA) with a Overweight rating and announces Price Target of $30.